Advances in Primary Biliary Cholangitis: Expert Insights on Emerging Data and Key Treatment Innovations - Episode 3

Assessing Disease Severity and Progression Risk in PBC

Published on: February 2, 2026

Frances Lee, MD, Aparna Goel, MD, A. Sidney Barritt IV, MD, MSCR, Lance L. Stein, MD

Explore the complexities of Primary Biliary Cholangitis (PBC), including risk factors, disease progression, and essential comorbidities for effective management.

EP. 1: An Overview of PBC Pathophysiology, Severity, and Burden

EP. 2: Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health

Now Viewing

EP. 3: Assessing Disease Severity and Progression Risk in PBC

EP. 4: Diagnostic Criteria in PBC: What Clinicians are Looking For

EP. 5: Experts Review the First- and Second-Line Treatment Options for PBC

EP. 6: How Special Populations and Disease Risk Impact Treatment Assessment in PBC

EP. 7: The Efficacy of PPAR Agonists in PBC: Signals of Extrahepatic Improvements

EP. 8: The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data

In “Assessing Disease Severity and Progression Risk in PBC,” our panel of experts delve into common comorbidities that patients with primary biliary cholangitis (PBC) have and how they manage complex cases.

Led by the moderator, the panelists examine the following critical questions:

How does disease progression affect management and the long-term complications associated with primary biliary cholangitis?

Please discuss how patients with primary biliary cholangitis have an elevated risk of other comorbidities (autoimmune diseases, cardiovascular diseases, etc.) and how that impacts long-term decision making and care.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, “Diagnostic Criteria in PBC: What Clinicians are Looking For” further explores PBC, highlighting the three-point criteria they use to diagnose this disease.